7 Top Gainers In Healthcare Sector (TLSA, SWAV, CPRX...)

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. Tiziana Life Sciences PLC (TLSA)

Tiziana Life Sciences is a clinical stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology.

Gained 50.31% to close Thursday's (Apr.25) trading at $9.62.

News: The Company reported encouraging interim clinical data from an ongoing phase IIa trial with Milciclib in patients with advanced liver cancer.

The Independent Data Monitoring Committee (IDMC), which reviewed safety data from trial patients, has concluded that the administration of Milciclib to patients with advanced hepatocellular carcinoma ("HCC") was not associated with unexpected signs or signals of toxicity.

Near-term Catalyst:

Topline data from this phase IIa trial with Milciclib in patients with advanced liver cancer is expected to be available by the end of Q3 2019.

2. scPharmaceuticals Inc. (SCPH)

scPharmaceuticals is a pharmaceutical company whose lead product candidate is Furoscix, a treatment candidate for edema, or fluid overload, in patients with heart failure.

Gained 18.03% to close Thursday's trading at $3.60.

News: No news

Near-term Catalyst:

The Company anticipates refiling the NDA for Furoscix, a treatment candidate for edema, or fluid overload, in patients with heart failure, by the end of 2020.

Furoscix was turned down by the FDA last June, and the Company was asked to conduct additional human factors studies, device modifications, and potentially a clinical validation study.

3. Diffusion Pharmaceuticals Inc. (DFFN)

Gained 15.36% to close Thursday's trading at $3.38.

News: No news

Clinical Trials:

The Company's lead drug candidate is Trans Sodium Crocinate.

A phase III study of Trans Sodium Crocinate to target inoperable glioblastoma multiforme brain cancer, dubbed INTACT, is underway. The Company was given FDA clearance last September to conduct a phase II on-ambulance trial of Trans Sodium Crocinate for the treatment of stroke, named PHAST-TSC.

Cash position:

Diffusion had cash and cash equivalents of $8.0 million as of December 31, 2018. The Company believes its cash and cash equivalents are sufficient to fund operations into July 2019.

4. Liquidia Technologies Inc. (LQDA)

Liquidia is a late-stage clinical biopharmaceutical company developing human therapeutics using its proprietary PRINT technology.

Gained 13.34% to close Thursday's trading at $9.26.

News: No news

Near-term Catalyst:

The Company is slated to report first-quarter 2019 financial results on Thursday, May 2, 2019.

5. Innovate Biopharmaceuticals Inc. (INNT)

Innovate Biopharmaceuticals is a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases.

Gained 12.71% to close Thursday's trading at $2.04.

News: No news

Near-term Catalysts:

-- The first phase III study of Larazotide acetate for celiac disease is expected to start this quarter. -- The pre-clinical studies of Larazotide acetate for non-alcoholic steatohepatitis (NASH) and alcoholic steatohepatitis (ASH) are set to continue.

6. ShockWave Medical Inc. (SWAV)

ShockWave Medical is a commercial-stage medical device company developing and marketing products based on intravascular lithotripsy (IVL) technology to treat calcified cardiovascular disease.

Gained 11.71% to close Thursday's trading at $38.54.

News: No news

Recent event:

On March 7, 2019, the Company went public on the Nasdaq Global Select Market, offering its shares at a price of $17 each.

Near-term Catalyst:

The Company is slated to report financial results for the first quarter of 2019 after market close on Wednesday, May 8, 2019. This is its first earnings report as a public company.

7. Catalyst Pharmaceuticals Inc. (CPRX)

Catalyst Pharma is a biopharmaceutical company developing therapies for people with rare debilitating, chronic neuromuscular and neurological diseases.

Gained 11.32% to close Thursday's trading at $6.00.

News: No news

Near-term Catalysts:

-- Completion of enrollment in phase III clinical trial of Firdapse in patients with muscle-specific kinase (MuSK) antibody positive myasthenia gravis (MuSK-MG). -- Completion of enrollment in phase III clinical trial of Firdapse in patients with Congenital Myasthenic Syndromes. -- Top-line results from phase III trial of Firdapse for MuSK-MG expected in the second half of 2019. -- Top-line results from phase III trial of Firdapse for Congenital Myasthenic Syndromes expected in the second half of 2019. -- Top-line results from proof-of-concept phase II trial of Firdapse in ambulatory patients with spinal muscular atrophy (SMA) type 3 expected in the first half of 2020.